NEW YORK (GenomeWeb) – Shares of Exact Sciences tumbled nearly 15 percent on Wednesday as investors were spooked by a study abstract that presented data suggesting a liquid biopsy test for colorectal cancer screening could rival the performance of Exact Science's Cologuard test.

Industry analysts, however, were not convinced that the new test should be considered a competitive threat yet, and many said the dip in Exact Sciences' stock price represented a buying opportunity.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.